ReviewCancers2025
Protein and Peptide in Cancer Research: From Biomarker to Biotherapeutics.
Review in Cancers, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Proteins and peptides play a pivotal role in key pathological processes, including cancer growth, immune evasion, angiogenesis, and metastasis. Consequently, they are gaining attention as significant biomolecules in the diagnosis and treatment of various diseases. This review provides a comprehensive overview of the latest research trends and technological advancements in protein- and peptide-based cancer diagnostic and therapeutic strategies. It covers the clinical application of major diagnostic markers such as PSA, CA125, HER2, and AFP, as well as therapeutic strategies including monoclonal antibodies, immune checkpoint inhibitors, and anticancer peptides. Additionally, it introduces quantitative analysis techniques such as ELISA, mass spectrometry, and CyTOF, as well as advancements in delivery systems based on nanoparticle-peptide complexes. Peptides offer advantages for precision therapy due to their high target specificity and structural modifiability. However, they also have limitations such as stability, enzymatic degradation, and delivery efficiency. Emerging technologies such as synthetic biology, computational design, and omics-integrated analysis are being developed to address these challenges, and rapid advancements in this field are enhancing the potential for clinical application. This review underscores the potential of protein- and peptide-based strategies for precision cancer diagnosis and personalized therapy and proposes future research directions in this field.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.